IRIS Accounts Production v25.4.0.155 01446445 Board of Directors 31.3.25 1.4.24 31.3.25 31.3.25 Medium entities These accounts have been prepared in accordance with the provisions applicable to companies subject to the medium-sized companies regime. true true true false true true false false false false true false Fair value model Ordinary 0 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh014464452024-03-31014464452025-03-31014464452024-04-012025-03-31014464452023-03-31014464452023-04-012024-03-31014464452024-03-3101446445ns15:EnglandWales2024-04-012025-03-3101446445ns14:PoundSterling2024-04-012025-03-3101446445ns10:Director12024-04-012025-03-3101446445ns10:Consolidated2025-03-3101446445ns10:ConsolidatedGroupCompanyAccounts2024-04-012025-03-3101446445ns10:PrivateLimitedCompanyLtd2024-04-012025-03-3101446445ns10:Consolidatedns10:MediumEntities2024-04-012025-03-3101446445ns10:Consolidatedns10:Audited2024-04-012025-03-3101446445ns10:Medium-sizedCompaniesRegimeForDirectorsReport2024-04-012025-03-3101446445ns10:Medium-sizedCompaniesRegimeForAccounts2024-04-012025-03-3101446445ns10:Consolidated2024-04-012025-03-3101446445ns10:Consolidatedns10:Medium-sizedCompaniesRegimeForDirectorsReport2024-04-012025-03-3101446445ns10:Consolidatedns10:Medium-sizedCompaniesRegimeForAccounts2024-04-012025-03-3101446445ns10:FullAccounts2024-04-012025-03-3101446445ns5:Subsidiary12024-04-012025-03-310144644512024-04-012025-03-3101446445ns10:OrdinaryShareClass12024-04-012025-03-3101446445ns10:Director22024-04-012025-03-3101446445ns10:Director32024-04-012025-03-3101446445ns10:RegisteredOffice2024-04-012025-03-3101446445ns10:Consolidated2023-04-012024-03-3101446445ns5:CurrentFinancialInstruments2025-03-3101446445ns5:CurrentFinancialInstruments2024-03-3101446445ns5:ShareCapital2025-03-3101446445ns5:ShareCapital2024-03-3101446445ns5:CapitalRedemptionReserve2025-03-3101446445ns5:CapitalRedemptionReserve2024-03-3101446445ns5:RetainedEarningsAccumulatedLosses2025-03-3101446445ns5:RetainedEarningsAccumulatedLosses2024-03-3101446445ns5:ShareCapital2023-03-3101446445ns5:RetainedEarningsAccumulatedLosses2023-03-3101446445ns5:CapitalRedemptionReserve2023-03-3101446445ns5:RetainedEarningsAccumulatedLosses2023-04-012024-03-3101446445ns5:CapitalRedemptionReserve2023-04-012024-03-3101446445ns5:RetainedEarningsAccumulatedLosses2024-04-012025-03-3101446445ns5:CapitalRedemptionReserve2024-04-012025-03-310144644512024-04-012025-03-3101446445ns5:NetGoodwill2024-04-012025-03-3101446445ns5:LandBuildingsns5:OwnedOrFreeholdAssets2024-04-012025-03-3101446445ns5:PlantMachinery2024-04-012025-03-3101446445ns5:FurnitureFittings2024-04-012025-03-3101446445ns5:MotorVehicles2024-04-012025-03-3101446445ns5:ComputerEquipment2024-04-012025-03-3101446445ns5:LandBuildings2024-03-3101446445ns5:PlantMachinery2024-03-3101446445ns5:FurnitureFittings2024-03-3101446445ns5:ComputerEquipment2024-03-3101446445ns5:LandBuildings2024-04-012025-03-3101446445ns5:LandBuildings2025-03-3101446445ns5:PlantMachinery2025-03-3101446445ns5:FurnitureFittings2025-03-3101446445ns5:ComputerEquipment2025-03-3101446445ns5:LandBuildings2024-03-3101446445ns5:PlantMachinery2024-03-3101446445ns5:FurnitureFittings2024-03-3101446445ns5:ComputerEquipment2024-03-3101446445ns5:CostValuation2024-03-31014464451ns5:Subsidiary12024-04-012025-03-3101446445ns5:WithinOneYearns5:CurrentFinancialInstruments2025-03-3101446445ns5:WithinOneYearns5:CurrentFinancialInstruments2024-03-3101446445ns5:AcceleratedTaxDepreciationDeferredTax2025-03-3101446445ns5:AcceleratedTaxDepreciationDeferredTax2024-03-3101446445ns5:TaxLossesCarry-forwardsDeferredTax2025-03-3101446445ns5:TaxLossesCarry-forwardsDeferredTax2024-03-3101446445ns5:BetweenOneTwoYearsns5:Non-currentFinancialInstruments2025-03-3101446445ns5:BetweenOneTwoYearsns5:Non-currentFinancialInstruments2024-03-3101446445ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2025-03-3101446445ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2024-03-3101446445ns5:DeferredTaxation2024-03-3101446445ns5:DeferredTaxation2024-04-012025-03-3101446445ns5:DeferredTaxation2025-03-3101446445ns10:OrdinaryShareClass12025-03-3101446445ns5:RetainedEarningsAccumulatedLosses2024-03-3101446445ns5:CapitalRedemptionReserve2024-03-31
















EAGLE SCIENTIFIC LIMITED

GROUP STRATEGIC REPORT, REPORT OF THE DIRECTORS AND

CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2025






EAGLE SCIENTIFIC LIMITED (REGISTERED NUMBER: 01446445)

CONTENTS OF THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025










Page

Company Information 1

Group Strategic Report 2

Report of the Directors 4

Report of the Independent Auditors 6

Consolidated Income Statement 10

Consolidated Other Comprehensive Income 11

Consolidated Balance Sheet 12

Company Balance Sheet 13

Consolidated Statement of Changes in Equity 14

Company Statement of Changes in Equity 15

Consolidated Cash Flow Statement 16

Notes to the Consolidated Financial Statements 17


EAGLE SCIENTIFIC LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 MARCH 2025







DIRECTORS: T J Johnsen
V K Mehan
Mrs D L Dunn



REGISTERED OFFICE: Regent House
Lenton Street
Sandiacre
Nottingham
Nottinghamshire
NG10 5DJ



REGISTERED NUMBER: 01446445 (England and Wales)



SENIOR STATUTORY AUDITOR: Hari Vasdev MEng FCA



AUDITORS: Sibbalds Limited
Chartered Accountants and Statutory Auditor
Sixth Floor
Cavendish Building
1 Agard Street
Derby
Derbyshire
DE1 1DZ

EAGLE SCIENTIFIC LIMITED (REGISTERED NUMBER: 01446445)

GROUP STRATEGIC REPORT
FOR THE YEAR ENDED 31 MARCH 2025


The directors present their strategic report of the company and the group for the year ended 31 March 2025.

BUSINESS REVIEW
The Directors look at turnover, margins and profitability when monitoring business performance. The aftermath of COVID 19 within the regions the group operates has continued to affect sales with our clients rebuilding their budgets. Turnover increased within the group from £5.07m to £5.36m which is an 5.7% increase. Gross profit margins have increased from 15.7% to 34.4%. The Board also consider key statement of financial position areas in order to understand the financial position of the group, and this shows a net asset position of £3.12m at the year end which is down from £3.15m last year. Despite the decrease, the group's net asset position is stable.

Eagle Scientific Ltd

The company has continued to reduce overhead in response to the extended downturn in business caused by the COVID 19 pandemic. The company continues to work on a number of new long-term projects and is fully engaged with long-term contracts with UN agencies and NGO's. New contracts with our traditional markets have been agreed and will give a large boost to turnover during 2026. There are a number of very large contracts that will now fall into 2025-2026.

Cooper Research Technology Ltd

Cooper continues to recover from the effects of COVID 19. Trading results for the next financial year are expected to be positive. The company continues to develop new products and update the existing range.

Mercol Engineering Ltd

Mercol Engineering Ltd ceased trading at the end of the last financial year and employees of Mercol were transferred to the subsidiary Cooper Research Technology Ltd. The accounts are prepared on a basis other than going concern basis.

James Cox & Sons Inc.

The Company continues to trade well. The upturn in the USA market has continued and demand for testing in the Asphalt sector remains strong. As a domestic supplier, James Cox enjoys considerable support as the USA continues to support reshoring of manufacturing.

PRINCIPAL RISKS AND UNCERTAINTIES
The usual long-term risks exist due to financial constraints on our customers that are recovering from the knock-on effects of COVID 19. Fluctuating costs for freight continue to make the pricing of long-term projects difficult.

FINANCIAL INSTRUMENTS AND RISK MANAGEMENT
The group's financial assets and liabilities consist of trade debtors and creditors, cash balances, bank loans and overdrafts. The directors manage the group's exposure to financial risk by researching the credit worthiness of customers and by seeking advice from the group's providers of finance and its other external financial advisers. Currency risk is managed by holding Dollar and Euro bank accounts and where necessary by the use of forward contracts. The group does not trade speculatively in derivatives or similar instruments.

LIQUIDITY RISK
The Eagle Scientific group ensures that sufficient funds are available for the day to day operations of its subsidiaries.


EAGLE SCIENTIFIC LIMITED (REGISTERED NUMBER: 01446445)

GROUP STRATEGIC REPORT
FOR THE YEAR ENDED 31 MARCH 2025

RESEARCH AND DEVELOPMENT
Cooper Research Technology Limited has continued the development of new products within the Asphalt Testing sector for both industrial and research purposes.

ON BEHALF OF THE BOARD:





T J Johnsen - Director


23 December 2025

EAGLE SCIENTIFIC LIMITED (REGISTERED NUMBER: 01446445)

REPORT OF THE DIRECTORS
FOR THE YEAR ENDED 31 MARCH 2025


The directors present their report with the financial statements of the company and the group for the year ended 31 March 2025.

PRINCIPAL ACTIVITY
The principal activity of the group in the year under review was that of the design, manufacture and supply of high-performance materials testing equipment plus scientific, medical, educational and vocational training solutions.

DIVIDENDS
No dividends will be distributed for the year ended 31 March 2025.

DIRECTORS
The directors shown below have held office during the whole of the period from 1 April 2024 to the date of this report.

T J Johnsen
V K Mehan
Mrs D L Dunn

DISCLOSURE IN THE STRATEGIC REPORT
Certain matters required by regulation to be dealt with in the Report of the Directors have been dealt with in the Strategic Report. These include financial instruments and research and development.

STATEMENT OF DIRECTORS' RESPONSIBILITIES
The directors are responsible for preparing the Group Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law), including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the group and of the profit or loss of the group for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's and the group's transactions and disclose with reasonable accuracy at any time the financial position of the company and the group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

EAGLE SCIENTIFIC LIMITED (REGISTERED NUMBER: 01446445)

REPORT OF THE DIRECTORS
FOR THE YEAR ENDED 31 MARCH 2025


STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS
So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the group's auditors are unaware, and each director has taken all the steps that he or she ought to have taken as a director in order to make himself or herself aware of any relevant audit information and to establish that the group's auditors are aware of that information.

ON BEHALF OF THE BOARD:





T J Johnsen - Director


23 December 2025

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF
EAGLE SCIENTIFIC LIMITED


Opinion
We have audited the financial statements of Eagle Scientific Limited (the 'parent company') and its subsidiaries (the 'group') for the year ended 31 March 2025 which comprise the Consolidated Income Statement, Consolidated Other Comprehensive Income, Consolidated Balance Sheet, Company Balance Sheet, Consolidated Statement of Changes in Equity, Company Statement of Changes in Equity, Consolidated Cash Flow Statement and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:
-give a true and fair view of the state of the group's and of the parent company affairs as at 31 March 2025 and of the group's loss for the year then ended;
-have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
-have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and the parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information
The directors are responsible for the other information. The other information comprises the information in the Group Strategic Report and the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF
EAGLE SCIENTIFIC LIMITED


Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Group Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Group Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception
In the light of the knowledge and understanding of the group and the parent company and its environment obtained in the course of the audit, we have not identified material misstatements in the Group Strategic Report or the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
- adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of directors
As explained more fully in the Statement of Directors' Responsibilities set out on page four, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the group's and the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the group or the parent company or to cease operations, or have no realistic alternative but to do so.

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF
EAGLE SCIENTIFIC LIMITED


Auditors' responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

As part of our planning process:
- We enquired of management the systems and controls the company has in place, the areas of the financial statements that are mostly susceptible to the risk of irregularities and fraud, and whether there was any known, suspected or alleged fraud. The company did not inform us of any known, suspected or alleged fraud.
- We obtained an understanding of the legal and regulatory frameworks applicable to the company. We determined that the following were most relevant: FRS 102 and Companies Act 2006.
- We considered the incentives and opportunities that exist in the company, including the extent of management bias, which present a potential for irregularities and fraud to be perpetuated, and tailored our risk assessment accordingly.
-Using our knowledge of the company, together with the discussions held with the company at the planning stage, we formed a conclusion on the risk of misstatement due to irregularities including fraud and tailored our procedures according to this risk assessment.

The key procedures we undertook to detect irregularities including fraud during the course of the audit included:
- Identifying and testing journal entries and the overall accounting records, in particular those that were significant and unusual.
- Reviewing the financial statement disclosures and determining whether accounting policies have been appropriately applied.
- Testing key revenue lines, in particular cut-off, for evidence of management bias.
- Obtaining third-party confirmation of material bank balances.
- Documenting and verifying all significant related party and consolidated balances and transactions.
-Reviewing sensitive expense accounts for evidence of non-compliance with laws and regulations or fraud.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

As part of an audit in accordance with ISAs (UK), we exercise professional judgement and maintain professional scepticism throughout the audit. We also:
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF
EAGLE SCIENTIFIC LIMITED

- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group or the parent company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Report of the Auditors to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Report of the Auditors. However, future events or conditions may cause the group or the parent company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to express and opinion on the consolidated financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.




Hari Vasdev MEng FCA (Senior Statutory Auditor)
for and on behalf of Sibbalds Limited
Chartered Accountants and Statutory Auditor
Sixth Floor
Cavendish Building
1 Agard Street
Derby
Derbyshire
DE1 1DZ

23 December 2025

EAGLE SCIENTIFIC LIMITED (REGISTERED NUMBER: 01446445)

CONSOLIDATED INCOME STATEMENT
FOR THE YEAR ENDED 31 MARCH 2025

2025 2024
Notes £    £   

TURNOVER 3 5,360,002 5,067,095

Cost of sales 3,517,616 4,271,341
GROSS PROFIT 1,842,386 795,754

Administrative expenses 2,535,578 2,936,905
(693,192 ) (2,141,151 )

Other operating income 689,529 736,278
Gain/loss on revaluation of investment
property

-

(54,000

)
OPERATING LOSS 5 (3,663 ) (1,458,873 )

Interest receivable and similar income 4,319 2,553
656 (1,456,320 )

Interest payable and similar expenses 7 227,584 134,617
LOSS BEFORE TAXATION (226,928 ) (1,590,937 )

Tax on loss 8 (196,206 ) (69,668 )
LOSS FOR THE FINANCIAL YEAR (30,722 ) (1,521,269 )
Loss attributable to:
Owners of the parent (30,722 ) (1,521,269 )

EAGLE SCIENTIFIC LIMITED (REGISTERED NUMBER: 01446445)

CONSOLIDATED OTHER COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 MARCH 2025

2025 2024
Notes £    £   

LOSS FOR THE YEAR (30,722 ) (1,521,269 )


OTHER COMPREHENSIVE INCOME
Foreign exchange differences (3,358 ) (2,255 )
Income tax relating to other comprehensive
income

-

-

OTHER COMPREHENSIVE INCOME FOR THE
YEAR, NET OF INCOME TAX

(3,358

)

(2,255

)
TOTAL COMPREHENSIVE INCOME FOR THE
YEAR

(34,080

)

(1,523,524

)

Total comprehensive income attributable to:
Owners of the parent (34,080 ) (1,523,524 )

EAGLE SCIENTIFIC LIMITED (REGISTERED NUMBER: 01446445)

CONSOLIDATED BALANCE SHEET
31 MARCH 2025

2025 2024
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 10 37,452 67,415
Tangible assets 11 929,684 975,725
Investments 12 - -
Investment property 13 76,000 76,000
1,043,136 1,119,140

CURRENT ASSETS
Stocks 14 1,516,406 1,338,441
Debtors 15 2,883,341 3,208,778
Cash at bank and in hand 508,270 556,779
4,908,017 5,103,998
CREDITORS
Amounts falling due within one year 16 2,344,389 2,329,984
NET CURRENT ASSETS 2,563,628 2,774,014
TOTAL ASSETS LESS CURRENT LIABILITIES 3,606,764 3,893,154

CREDITORS
Amounts falling due after more than one
year

17

486,579

738,889
NET ASSETS 3,120,185 3,154,265

CAPITAL AND RESERVES
Called up share capital 22 150,000 150,000
Capital redemption reserve 23 50,000 50,000
Retained earnings 23 2,920,185 2,954,265
SHAREHOLDERS' FUNDS 3,120,185 3,154,265

The financial statements were approved and authorised for issue by the Board of Directors and authorised for issue on 23 December 2025 and were signed on its behalf by:





T J Johnsen - Director


EAGLE SCIENTIFIC LIMITED (REGISTERED NUMBER: 01446445)

COMPANY BALANCE SHEET
31 MARCH 2025

2025 2024
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 10 - -
Tangible assets 11 567,379 561,296
Investments 12 1,424,281 1,424,281
Investment property 13 76,000 76,000
2,067,660 2,061,577

CURRENT ASSETS
Stocks 14 125,900 99,467
Debtors 15 2,415,719 2,403,570
Cash at bank and in hand 426,244 444,020
2,967,863 2,947,057
CREDITORS
Amounts falling due within one year 16 754,321 716,824
NET CURRENT ASSETS 2,213,542 2,230,233
TOTAL ASSETS LESS CURRENT LIABILITIES 4,281,202 4,291,810

CAPITAL AND RESERVES
Called up share capital 22 150,000 150,000
Capital redemption reserve 23 50,000 50,000
Retained earnings 23 4,081,202 4,091,810
SHAREHOLDERS' FUNDS 4,281,202 4,291,810

Company's loss for the financial year (10,608 ) (891,001 )

The financial statements were approved and authorised for issue by the Board of Directors and authorised for issue on 23 December 2025 and were signed on its behalf by:





T J Johnsen - Director


EAGLE SCIENTIFIC LIMITED (REGISTERED NUMBER: 01446445)

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2025

Called up Capital
share Retained redemption Total
capital earnings reserve equity
£    £    £    £   
Balance at 1 April 2023 150,000 4,477,789 50,000 4,677,789

Changes in equity
Total comprehensive income - (1,523,524 ) - (1,523,524 )
Balance at 31 March 2024 150,000 2,954,265 50,000 3,154,265

Changes in equity
Total comprehensive income - (34,080 ) - (34,080 )
Balance at 31 March 2025 150,000 2,920,185 50,000 3,120,185

EAGLE SCIENTIFIC LIMITED (REGISTERED NUMBER: 01446445)

COMPANY STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2025

Called up Capital
share Retained redemption Total
capital earnings reserve equity
£    £    £    £   
Balance at 1 April 2023 150,000 4,982,811 50,000 5,182,811

Changes in equity
Total comprehensive income - (891,001 ) - (891,001 )
Balance at 31 March 2024 150,000 4,091,810 50,000 4,291,810

Changes in equity
Total comprehensive income - (10,608 ) - (10,608 )
Balance at 31 March 2025 150,000 4,081,202 50,000 4,281,202

EAGLE SCIENTIFIC LIMITED (REGISTERED NUMBER: 01446445)

CONSOLIDATED CASH FLOW STATEMENT
FOR THE YEAR ENDED 31 MARCH 2025

2025 2024
Notes £    £   
Cash flows from operating activities
Cash generated from operations 29 340,489 (1,108,631 )
Interest paid (227,584 ) (134,617 )
Tax paid 27,759 172,778
Net cash from operating activities 140,664 (1,070,470 )

Cash flows from investing activities
Purchase of tangible fixed assets (32,405 ) (25,976 )
Sale of tangible fixed assets 7,084 (691 )
Interest received 4,319 2,553
Net cash from investing activities (21,002 ) (24,114 )

Cash flows from financing activities
New loans in year 250,000 800,000
Loan repayments in year (672,940 ) (69,888 )
Amount introduced by directors 256,239 130,000
Amount withdrawn by directors (1,470 ) -
Net cash from financing activities (168,171 ) 860,112

Decrease in cash and cash equivalents (48,509 ) (234,472 )
Cash and cash equivalents at beginning of
year

30

556,779

791,251

Cash and cash equivalents at end of year 30 508,270 556,779

EAGLE SCIENTIFIC LIMITED (REGISTERED NUMBER: 01446445)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025


1. STATUTORY INFORMATION

Eagle Scientific Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the General Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

Basis of consolidation
The consolidated financial statements incorporate the financial statements of the company and all of its subsidiary undertakings. The acquisition method of accounting has been adopted.

Related party exemption
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Transactions between group entities which have been eliminated on consolidation are not disclosed within the financial statements.

Critical accounting judgements and key sources of estimation uncertainty
In the application of the group's accounting policies, the directors are required to make judgements, estimates and assumptions regarding the carrying amounts of the group's assets and liabilities. These are based on historical experience and other factors that are considered relevant. They are reviewed on a regular basis and changes recognised in the period in which the estimate is revised. Actual results may differ from these estimates.

The following are the critical accounting judgements and key sources of estimation uncertainty:

Intangible and tangible fixed assets are amortised or depreciated over their useful economic lives taking into account their residual values where appropriate. The actual lives of the assets and residual values are assessed annually and may vary depending on a number of factors. In re-assessing the asset lives, factors such as technological innovation, product life cycles and maintenance programmes are taken into account. Residual values consider such things as future market conditions, the remaining life of the asset and projected disposal values.

The recoverability of debtors is assessed on the likelihood and circumstances of the particular charge.

The value of stock is assessed for impairment. In re-assessing the stock value, factors such as slow movement and obsolescence are taken into account.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Turnover is recognised when the group has transferred the significant risks and rewards of ownership to the buyer and it is probable that the group will receive the previously agreed upon payment.

EAGLE SCIENTIFIC LIMITED (REGISTERED NUMBER: 01446445)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


2. ACCOUNTING POLICIES - continued

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2016, is being amortised evenly over its estimated useful life of ten years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Freehold property - 2% on cost
Plant and machinery - 33% on reducing balance and 25% on reducing balance
Fixtures and fittings - 33% on reducing balance, 25% on reducing balance and 4% on cost
Motor vehicles - 25% on reducing balance
Computer equipment - 33% on reducing balance, 25% on reducing balance and 15% on cost

Investment property
Investment property is shown at most recent valuation. Any aggregate surplus or deficit arising from changes in fair value is recognised in profit or loss.

Stocks and work in progress
Stocks and work in progress are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Cost is calculated using the first-in, first-out method and includes all purchase, transport, and handling costs in bringing stocks to their present location and condition.

For certain work in progress and finished goods manufactured by the group, cost is taken as production cost, which includes an appropriate proportion of attributable overheads.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Consolidated Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development
Expenditure on research and development is written off in the year in which it is incurred.


EAGLE SCIENTIFIC LIMITED (REGISTERED NUMBER: 01446445)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


2. ACCOUNTING POLICIES - continued

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The group operates a defined contribution pension scheme. Contributions payable to the group's pension scheme are charged to profit or loss in the period to which they relate.

Financial assets and liabilities
Short term debtors are measured at transaction price, less any impairment. Other financial assets, including loans to group companies are measured initially at fair value, net of transactions cost and are subsequently measured at amortised cost using the effective interest method, less any impairment.

Short term creditors are measured at transaction price. Other financial liabilities, including loans from group companies are measured initially at fair value, net of transaction cost and are measured subsequently at amortised cost using the effective interest method, less any impairment.

Going concern
The Directors have prepared budgets and cashflow forecasts for a period of at least 12 months from the date of these financial statements. These forecasts are based on current market and economic conditions. The results of these forecasts show good improvement in both turnover and gross profit margins and thus cash generation. The historic trading results have included the impact in downturn of trading following flooding that damaged premises in November 2023. The impact of this flooding has now finished and per forecasts assessed, after support from insurers as well as a pick up in trading post recovery from the floods, the company is expected to continue to trade positively in the future and providing confidence of the companies ability to continue as a going concern.

The business continues to take on new contracts therefore the Directors are confident that the business will actually exceed the prepared budgets which have been prepared cautiously and thus be able to fulfil its financial obligations. The business therefore continues to adopt the going concern policy in preparing its financial statements.

3. TURNOVER

The turnover and loss before taxation are attributable to the one principal activity of the group.

An analysis of turnover by geographical market is given below:

2025 2024
£    £   
United Kingdom 471,423 533,404
Europe 593,388 722,314
Rest of the world 4,295,191 3,811,377
5,360,002 5,067,095

EAGLE SCIENTIFIC LIMITED (REGISTERED NUMBER: 01446445)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


4. EMPLOYEES AND DIRECTORS
2025 2024
£    £   
Wages and salaries 1,793,601 1,918,110
Social security costs 170,106 170,489
Other pension costs 37,686 52,551
2,001,393 2,141,150

The average number of employees during the year was as follows:
2025 2024

Administrative 36 36
Operational 16 17
52 53

2025 2024
£    £   
Directors' remuneration 140,057 37,890
Directors' pension contributions to money purchase schemes 1,185 1,137

The number of directors to whom retirement benefits were accruing was as follows:

Money purchase schemes 1 1

5. OPERATING LOSS

The operating loss is stated after charging/(crediting):

2025 2024
£    £   
Operating lease payments 20,505 26,054
Other operating leases 51,054 94,608
Depreciation - owned assets 75,967 88,939
(Profit)/loss on disposal of fixed assets (4,834 ) 8,821
Goodwill amortisation 29,963 29,963
Auditors' remuneration 21,500 33,100
Foreign exchange differences 34,635 59,227

6. EXCEPTIONAL ITEMS
2025 2024
£    £   
Exceptional items (5,990 ) (36,776 )

The above in the prior year relates to costs incurred in clearing up the warehouse following the flooding of the premises in late 2023.

EAGLE SCIENTIFIC LIMITED (REGISTERED NUMBER: 01446445)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


7. INTEREST PAYABLE AND SIMILAR EXPENSES
2025 2024
£    £   
Bank loan interest 224,893 134,617
HMRC interest paid 2,691 -
227,584 134,617

8. TAXATION

Analysis of the tax credit
The tax credit on the loss for the year was as follows:
2025 2024
£    £   
Current tax:
UK corporation tax 627 7,299
Prior year tax adjustment (187,606 ) (30,643 )
Total current tax (186,979 ) (23,344 )

Deferred tax (9,227 ) (46,324 )
Tax on loss (196,206 ) (69,668 )

Reconciliation of total tax credit included in profit and loss
The tax assessed for the year is lower than the standard rate of corporation tax in the UK. The difference is explained below:

2025 2024
£    £   
Loss before tax (226,928 ) (1,590,937 )
Loss multiplied by the standard rate of corporation tax in the UK of 19 %
(2024 - 19 %)

(43,116

)

(302,278

)

Effects of:
Expenses not deductible for tax purposes 4,595 15,541
Adjustments to tax charge in respect of previous periods (187,606 ) (30,643 )
Effect of goodwill amortisation 5,692 5,692
Other permanent differences (9,518 ) (20,739 )
Deferred tax asset not provided on losses 38,077 283,652
Effect of stock PURP (4,330 ) (20,893 )
Total tax credit (196,206 ) (69,668 )

Tax effects relating to effects of other comprehensive income

2025
Gross Tax Net
£    £    £   
Foreign exchange differences (3,358 ) - (3,358 )

EAGLE SCIENTIFIC LIMITED (REGISTERED NUMBER: 01446445)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


8. TAXATION - continued

2024
Gross Tax Net
£    £    £   
Foreign exchange differences (2,255 ) - (2,255 )

In his budget of 3 March 2021. the Chancellor of the Exchequer announced that the UK corporation tax rate would increase to 25% for companies with profits over £250,000 for the year starting 1 April 2023. This has been reflected in the company's financial statements in the current and future years and deferred tax has subsequently been provided at this rate. This will impact the amount of future cash tax payments made by the company.

In the future, the company expects to be able to continue to claim capital allowances in excess of depreciation.

9. INDIVIDUAL INCOME STATEMENT

As permitted by Section 408 of the Companies Act 2006, the Income Statement of the parent company is not presented as part of these financial statements.


10. INTANGIBLE FIXED ASSETS

Group
Goodwill
£   
COST
At 1 April 2024
and 31 March 2025 299,628
AMORTISATION
At 1 April 2024 232,213
Amortisation for year 29,963
At 31 March 2025 262,176
NET BOOK VALUE
At 31 March 2025 37,452
At 31 March 2024 67,415

EAGLE SCIENTIFIC LIMITED (REGISTERED NUMBER: 01446445)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


11. TANGIBLE FIXED ASSETS

Group
Improvements
Freehold to Plant and
property property machinery
£    £    £   
COST
At 1 April 2024 1,098,211 4,675 450,410
Additions - - 7,821
Disposals - - -
Exchange differences - (94 ) (995 )
At 31 March 2025 1,098,211 4,581 457,236
DEPRECIATION
At 1 April 2024 321,681 1,233 335,292
Charge for year 18,864 100 39,065
Eliminated on disposal - - -
Exchange differences - 12 (1,254 )
At 31 March 2025 340,545 1,345 373,103
NET BOOK VALUE
At 31 March 2025 757,666 3,236 84,133
At 31 March 2024 776,530 3,442 115,118

Fixtures
and Motor Computer
fittings vehicles equipment Totals
£    £    £    £   
COST
At 1 April 2024 379,916 79,708 48,487 2,061,407
Additions 23,945 - 639 32,405
Disposals - (18,399 ) - (18,399 )
Exchange differences (198 ) (246 ) - (1,533 )
At 31 March 2025 403,663 61,063 49,126 2,073,880
DEPRECIATION
At 1 April 2024 320,115 60,265 47,096 1,085,682
Charge for year 12,865 4,495 578 75,967
Eliminated on disposal - (16,149 ) - (16,149 )
Exchange differences 184 (246 ) - (1,304 )
At 31 March 2025 333,164 48,365 47,674 1,144,196
NET BOOK VALUE
At 31 March 2025 70,499 12,698 1,452 929,684
At 31 March 2024 59,801 19,443 1,391 975,725

EAGLE SCIENTIFIC LIMITED (REGISTERED NUMBER: 01446445)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


11. TANGIBLE FIXED ASSETS - continued

Group

Included in cost of land and buildings is freehold land of £155,000 (2024 - £155,000) which is not depreciated.

Company
Fixtures
Freehold Plant and and Computer
property machinery fittings equipment Totals
£    £    £    £    £   
COST
At 1 April 2024 809,903 13,146 38,023 48,487 909,559
Additions - - 23,525 639 24,164
At 31 March 2025 809,903 13,146 61,548 49,126 933,723
DEPRECIATION
At 1 April 2024 255,254 10,833 35,080 47,096 348,263
Charge for year 13,098 579 3,826 578 18,081
At 31 March 2025 268,352 11,412 38,906 47,674 366,344
NET BOOK VALUE
At 31 March 2025 541,551 1,734 22,642 1,452 567,379
At 31 March 2024 554,649 2,313 2,943 1,391 561,296

Included in cost of land and buildings is freehold land of £ 155,000 (2024 - £ 155,000 ) which is not depreciated.

12. FIXED ASSET INVESTMENTS

Company
Shares in
group
undertakings
£   
COST
At 1 April 2024
and 31 March 2025 1,424,281
NET BOOK VALUE
At 31 March 2025 1,424,281
At 31 March 2024 1,424,281

EAGLE SCIENTIFIC LIMITED (REGISTERED NUMBER: 01446445)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


12. FIXED ASSET INVESTMENTS - continued

The group or the company's investments at the Balance Sheet date in the share capital of companies include the following:

Subsidiaries

Cooper Research Technology Limited
Registered office: Regent House, Lenton Street, Sandiacre, Nottingham, Nottinghamshire, NG10 5DJ
Nature of business: Manufacturer of instruments for testing
%
Class of shares: holding
Ordinary 100.00

Mercol Engineering Limited
Registered office: Regent House, Lenton Street, Sandiacre, Nottingham, Nottinghamshire, NG10 5DG
Nature of business: Manufacturer of instruments for testing
%
Class of shares: holding
Ordinary 100.00

By virtue of the shares held in Cooper Research Technology Limited.

James Cox and Sons Inc.
Registered office: PO Box 674, Colfax CA95713, USA
Nature of business: Manufacturer of instruments for testing
%
Class of shares: holding
Ordinary 100.00

By virtue of the shares held in Cooper Research Technology Limited.


13. INVESTMENT PROPERTY

Group
Total
£   
FAIR VALUE
At 1 April 2024
and 31 March 2025 76,000
NET BOOK VALUE
At 31 March 2025 76,000
At 31 March 2024 76,000

EAGLE SCIENTIFIC LIMITED (REGISTERED NUMBER: 01446445)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


13. INVESTMENT PROPERTY - continued

Group

Fair value at 31 March 2025 is represented by:
£   
Valuation in 2024 (54,000 )
Valuation in 2023 (39,949 )
Cost 169,949
76,000

If investment property had not been revalued it would have been included at the following historical cost:

2025 2024
£    £   
Cost 169,949 169,949

Investment property was valued on an open market basis on 9 February 2024 by BB&J .

The valuation of Investment Property is based on management's assessment of the fair value at each reporting date.

Company
Total
£   
FAIR VALUE
At 1 April 2024
and 31 March 2025 76,000
NET BOOK VALUE
At 31 March 2025 76,000
At 31 March 2024 76,000

Fair value at 31 March 2025 is represented by:
£   
Valuation in 2024 (54,000 )
Valuation in 2023 (39,949 )
Cost 169,949
76,000

If investment property had not been revalued it would have been included at the following historical cost:

2025 2024
£    £   
Cost 169,949 169,949

Investment property was valued on an open market basis on 9 February 2024 by BB&J .

EAGLE SCIENTIFIC LIMITED (REGISTERED NUMBER: 01446445)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


14. STOCKS

Group Company
2025 2024 2025 2024
£    £    £    £   
Raw materials 432,004 383,346 - -
Work-in-progress 275,673 206,176 - -
Finished goods 808,729 748,919 125,900 99,467
1,516,406 1,338,441 125,900 99,467

15. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

Group Company
2025 2024 2025 2024
£    £    £    £   
Trade debtors 2,356,577 2,739,827 2,214,581 2,235,982
Amounts owed by group undertakings - - 73,808 -
Other debtors - 5,431 - -
Corporation tax 188,774 31,811 - -
VAT 12,114 52,570 10,975 29,031
Deferred tax asset 220,918 211,746 98,118 99,986
Prepayments and accrued income 104,958 167,393 18,237 38,571
2,883,341 3,208,778 2,415,719 2,403,570

Deferred tax asset
Group Company
2025 2024 2025 2024
£    £    £    £   
Accelerated capital allowances (45,930 ) (55,759 ) (17,030 ) (15,162 )
Tax losses carried forward 227,482 227,482 78,161 78,161
Other timing differences 39,366 40,023 36,987 36,987
220,918 211,746 98,118 99,986

EAGLE SCIENTIFIC LIMITED (REGISTERED NUMBER: 01446445)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


16. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

Group Company
2025 2024 2025 2024
£    £    £    £   
Bank loans and overdrafts (see note 18) 401,617 541,223 90,533 -
Trade creditors 850,805 986,947 151,397 297,184
Tax 4,927 7,239 - -
Social security and other taxes 88,700 113,188 21,933 22,415
Pension control - 5,286 - 5,286
Net wages control (2,648 ) 1,797 - 1,797
Other creditors 125,289 29,371 114,368 -
Directors' current accounts 604,769 350,000 348,587 350,000
Deferred income 7,213 3,500 - -
Accrued expenses 263,717 291,433 27,503 40,142
2,344,389 2,329,984 754,321 716,824

17. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

Group
2025 2024
£    £   
Bank loans (see note 18) 455,555 738,889
Other creditors 31,024 -
486,579 738,889

18. LOANS

An analysis of the maturity of loans is given below:

Group Company
2025 2024 2025 2024
£    £    £    £   
Amounts falling due within one year or on demand:
Bank loans - secured 401,617 541,223 90,533 -
Amounts falling due between one and two years:
Bank loans 1-2 years - secured 233,333 283,333 - -
Amounts falling due between two and five years:
Bank loans 2-5 years - secured 222,222 455,556 - -

EAGLE SCIENTIFIC LIMITED (REGISTERED NUMBER: 01446445)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


18. LOANS - continued

The CBILS loan is repayable in monthly instalments from November 2021 onwards and will be fully repaid in October 2026. Interest is charged at 3.99% above base rate. At the year end, the balance on the loan was £250,000.

The first Newable loan is repayable in monthly instalments from November 2023 onwards and will be fully repaid in October 2024. Interest is charged at 28.1% on the principal amount. At the year end, the balance on the loan was £488,889.

The FSE MEIC loan is repayable in monthly instalments from December 2023 onwards and will be fully repaid in November 2028. Interest is charged at 14.65%. At the year end, the balance on the loan was £27,750.

The second Newable loan is repayable in monthly instalments from April 2024 onwards and will be fully repaid in June 2025. Interest is charged at 19.2% on the principal amount. At the year end, the balance on the loan was £91,000.

19. LEASING AGREEMENTS

Minimum lease payments fall due as follows:

Group
Non-cancellable
operating leases
2025 2024
£    £   
Within one year 33,984 37,496
Between one and five years 9,533 43,517
43,517 81,013

20. SECURED DEBTS

The following secured debts are included within creditors:

Group
2025 2024
£    £   
Bank loans 857,172 1,280,112

See other financial commitments note for details of securities.

21. DEFERRED TAX

Group
£   
Balance at 1 April 2024 (211,746 )
Provided during year (9,172 )
Balance at 31 March 2025 (220,918 )

EAGLE SCIENTIFIC LIMITED (REGISTERED NUMBER: 01446445)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


21. DEFERRED TAX - continued

Company
£   
Balance at 1 April 2024 (99,986 )
Provided during year 1,868
Balance at 31 March 2025 (98,118 )

22. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2025 2024
value: £    £   
150,000 Ordinary £1 150,000 150,000

23. RESERVES

Group
Capital
Retained redemption
earnings reserve Totals
£    £    £   

At 1 April 2024 2,954,265 50,000 3,004,265
Deficit for the year (30,722 ) (30,722 )
Foreign exchange differences (3,358 ) - (3,358 )
At 31 March 2025 2,920,185 50,000 2,970,185

Company
Capital
Retained redemption
earnings reserve Totals
£    £    £   

At 1 April 2024 4,091,810 50,000 4,141,810
Deficit for the year (10,608 ) (10,608 )
At 31 March 2025 4,081,202 50,000 4,131,202


24. PENSION COMMITMENTS

The group operates a defined contribution pension scheme for the benefits of its employees. The costs of the scheme are recognised in the year in which contributions are payable are disclosed in the employees and directors note.

EAGLE SCIENTIFIC LIMITED (REGISTERED NUMBER: 01446445)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


25. CONTINGENT LIABILITIES

As part of the normal course of business, the group has given a number of guarantees secured by its bankers. The total amount guaranteed at the balance sheet date was £336,417 (2024 - £408,583).

26. OTHER FINANCIAL COMMITMENTS

The company has an undertaking to its bankers for full group security incorporating debentures and corporate guarantees for the group's borrowings dated 10 January 2017. The net amount outstanding to the bank in respect of the undertaking at 31 March 2025 was £NIL (2024 - £NIL).

The bank borrowings are secured by a fixed and floating charge over the assets of the group.

27. RELATED PARTY DISCLOSURES

During the year, £254,769 (2024 - £130,000) was advanced to the group by a director. At the year end, a balance of £604,769 (2024 - £350,000) was outstanding to the directors. These amounts are interest-free and repayable on demand.

During the year, the company also made several transactions amounting to a total of £950 (2024: £Nil) with the Westminster Africa Business Group, a committee that director Tim Johnsen is also the Vice Chairman of and which meets to discuss and strengthen business links between the UK and the African continent.

There was an accounts payable balance outstanding at the year end with Westminster Africa Business Group of £180 (2024: £Nil)

28. ULTIMATE CONTROLLING PARTY

The controlling party is T J Johnsen.

29. RECONCILIATION OF LOSS BEFORE TAXATION TO CASH GENERATED FROM OPERATIONS

2025 2024
£    £   
Loss before taxation (226,928 ) (1,590,937 )
Depreciation charges 105,930 118,903
(Profit)/loss on disposal of fixed assets (4,834 ) 8,821
Loss on revaluation of fixed assets - 54,000
Foreign exchange differences (3,129 ) (1,979 )
Finance costs 227,584 134,617
Finance income (4,319 ) (2,553 )
94,304 (1,279,128 )
(Increase)/decrease in stocks (177,965 ) 577,187
Decrease/(increase) in trade and other debtors 491,572 (85,822 )
Decrease in trade and other creditors (67,422 ) (320,868 )
Cash generated from operations 340,489 (1,108,631 )

EAGLE SCIENTIFIC LIMITED (REGISTERED NUMBER: 01446445)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025


30. CASH AND CASH EQUIVALENTS

The amounts disclosed on the Cash Flow Statement in respect of cash and cash equivalents are in respect of these Balance Sheet amounts:

Year ended 31 March 2025
31.3.25 1.4.24
£    £   
Cash and cash equivalents 508,270 556,779
Year ended 31 March 2024
31.3.24 1.4.23
£    £   
Cash and cash equivalents 556,779 1,203,670
Bank overdrafts - (412,419 )
556,779 791,251


31. ANALYSIS OF CHANGES IN NET DEBT

At 1.4.24 Cash flow At 31.3.25
£    £    £   
Net cash
Cash at bank and in hand 556,779 (48,509 ) 508,270
556,779 (48,509 ) 508,270
Debt
Debts falling due within 1 year (541,223 ) 139,606 (401,617 )
Debts falling due after 1 year (738,889 ) 283,334 (455,555 )
(1,280,112 ) 422,940 (857,172 )
Total (723,333 ) 374,431 (348,902 )